CDSCO Approves Durvalumab for Lung Cancer Treatment
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
Approved Indications: BEFORE, Durvalumab was approved in India primarily for non-small cell lung cancer (NSCLC) and biliary tract cancer. NOW, the CDSCO has officially expanded its approved indication to include limited-stage small cell lung cancer (LS-SCLC).
- ▶
Post-Chemoradiation Care: BEFORE, patients with LS-SCLC had very few targeted maintenance therapies available after completing initial platinum-based chemoradiation. NOW, Durvalumab is specifically approved as a follow-up immunotherapy for patients whose disease has not progressed following this initial treatment.
- ▶
Distribution Authorization: BEFORE, AstraZeneca could not officially market Imfinzi for small cell lung cancer in India without special off-label exemptions. NOW, the company has formal regulatory clearance to directly import, sell, and distribute the specific infusion doses for this exact demographic.
Prelims Angle
NCERT Connection
Practice Questions
Q1
Correct Statement(s)With reference to Durvalumab and lung cancer treatment, which of the following statements is/are correct? 1. Durvalumab is a targeted monoclonal antibody that functions as an immune checkpoint inhibitor. 2. Small cell lung cancer (SCLC) is generally less aggressive and spreads slower than non-small cell lung cancer (NSCLC).